Humana (NYSE:HUM) Price Target Raised to $344.00

Humana (NYSE:HUM) had its price objective lifted by investment analysts at Barclays from $180.00 to $344.00 in a report released on Tuesday,MarketScreener reports. Barclays‘s price objective indicates a potential upside of 12.93% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Evercore increased their price objective on shares of Humana from $195.00 to $250.00 in a research note on Thursday, April 30th. Wells Fargo & Company lowered shares of Humana from a “cautious” rating to a “reduce” rating in a research report on Wednesday, May 20th. Morgan Stanley lifted their price objective on shares of Humana from $146.00 to $217.00 and gave the company an “underweight” rating in a research note on Friday, May 15th. Piper Sandler restated a “neutral” rating and set a $254.00 price objective (up from $182.00) on shares of Humana in a research report on Wednesday, May 13th. Finally, The Goldman Sachs Group raised their target price on Humana from $158.00 to $195.00 and gave the company a “sell” rating in a report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $270.48.

Humana Price Performance

Humana stock opened at $304.61 on Tuesday. The firm has a market cap of $36.57 billion, a PE ratio of 32.58, a price-to-earnings-growth ratio of 2.86 and a beta of 0.68. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The stock’s fifty day moving average price is $221.01 and its two-hundred day moving average price is $227.45. Humana has a one year low of $163.11 and a one year high of $315.66.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The company had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same period in the prior year, the firm posted $11.58 EPS. Humana’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, research analysts expect that Humana will post 9.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Humana

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Edgestream Partners L.P. acquired a new stake in Humana in the first quarter valued at approximately $5,888,000. Kentucky Retirement Systems increased its holdings in shares of Humana by 69.8% during the first quarter. Kentucky Retirement Systems now owns 12,872 shares of the insurance provider’s stock worth $2,232,000 after buying an additional 5,293 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Humana by 8.8% during the first quarter. Janus Henderson Group PLC now owns 219,065 shares of the insurance provider’s stock worth $37,983,000 after buying an additional 17,629 shares in the last quarter. Centaurus Financial Inc. lifted its stake in shares of Humana by 126.7% in the 1st quarter. Centaurus Financial Inc. now owns 3,400 shares of the insurance provider’s stock valued at $590,000 after acquiring an additional 1,900 shares during the last quarter. Finally, South Dakota Investment Council boosted its holdings in shares of Humana by 42.0% during the 1st quarter. South Dakota Investment Council now owns 229,090 shares of the insurance provider’s stock valued at $39,722,000 after acquiring an additional 67,707 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.